DMTK News and Press, DermTech Inc From 01/31/24

- Ongoing emphasis on growing revenue for the DermTech Melanoma Test (DMT) - Approximately $40 million in total operating expense reductions compared to fiscal 2022 resulting from all restructuring actions DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in pr...

2024-01-18 15:04:11 ET More on DermTech DermTech, Inc. (DMTK) Q3 2023 Earnings Call Transcript DermTech stock rallies 18% on positive study for melanoma test DermTech Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on DermTech Historical ...

- Study demonstrated the DMT’s effectiveness as a melanoma rule-out test for all skin types - Negative predictive value (NPV) higher than 99% regardless of skin type DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a ...

- Trust 2 Study confirms negative predictive value (NPV) of 99.7% for the foundational gene expression assay - Optional TERT promoter mutation testing does not significantly alter sensitivity, NPV or positive predictive value (PPV) DermTech, Inc. (NASDAQ: DMTK) (DermTech or th...

2024-01-08 10:26:35 ET More on DermTech DermTech, Inc. (DMTK) Q3 2023 Earnings Call Transcript DermTech Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on DermTech Historical earnings data for DermTech Financial information for DermTech ...

- Trust 2 Study demonstrated powerful clinical utility for the DMT as a rule-out test for melanoma - Negative predictive value (NPV) higher than 99% DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomi...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In DermTech To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 a...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In DermTech To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 a...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In DermTech To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 a...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In DermTech To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 a...